• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clarus touts top-line results in phase III testosterone replacement study

Clarus touts top-line results in phase III testosterone replacement study

September 25, 2012
CenterWatch Staff

Clarus Therapeutics, a Northbrook, Ill.-based privately held biopharmaceutical company focused on oral T replacement products, released top-line results from its ongoing phase III study of CLR-610, a proprietary oral testosterone (T) replacement product.

In this positive-controlled study, data from the 90-day treatment phase demonstrate that 87% of the 141 men treated with CLR-610 achieved average serum T levels (C-avg) in the normal range (300-1,000ng/dL), the study's primary efficacy endpoint. The C-avg in men treated with CLR-610 was 624 ng/dL. This compares to the 80% of the 146 men in the T-gel comparison arm who achieved C-avg in the normal range. The C-avg in men treated with the T-gel comparison arm was 480 ng/dL.

"We are particularly excited about the significant number of men receiving CLR-610 who achieved normal T levels in this study," said Bela S. Denes, M.D., chief medical officer of Clarus. "Market research shows that men currently being treated for low T with transdermal or injectable products would overwhelmingly prefer an oral option. Thus, we believe CLR-610 will have strong appeal."

The study enrolled 325 men with low serum T (less than 300ng/dL) in 25 sites in the U.S. and five sites in Germany. Men were randomly assigned to receive CLR-610 or T-gel. Primary endpoint of the ongoing study is the percentage of men who achieve normal serum T levels after administration of CLR-610 for 90 days. At least 75% of men on day 90 must had an average serum T in the normal range to meet current FDA efficacy guidance for T replacement products.

Consistent with phase II results, there was no evidence of liver toxicity in men treated with CLR-610 or T-gel.

"The results observed thus far with CLR-610 are very encouraging and the feedback we received from trial participants at UCLA has been extremely positive," added Ronald S. Swerdloff, M.D., chief of the division of endocrinology, department of medicine at the Harbor-UCLA Medical Center and the principal investigator at the LA Biomedical Research Institute on the phase III study. "The convenience of an oral T replacement option is one that I believe patients and their healthcare providers will embrace."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing